Superior Features of Spironolactone Over Sulfonamide Diuretics for Treating Hypertension or CHF
The first selective aldosterone receptor antagonist, spironolactone (Aldactone), was introduced in clinical medicine in 1958. 2 By blocking the action of aldosterone, it proved to be a potent natriuretic-diuretic and K ϩ -retaining agent. Thus, it produced diuresis and weight loss with no loss of K ϩ or Mg 2ϩ , something our group views as a great conceptual therapeutic advantage over thiazides. The lack of any demonstrable morbidity from thiazide-induced K ϩ depletion and the impressive prompt diuresis that these drugs produced at a low cost, however, carried the sulfonamide diuretics into a leadership position for treatment of hypertension or edematous states that continues today.
Our preference for the aldosterone antagonist approach, however, was enhanced by 2 facts. First, in outpatient trials, in Ͼ20 reports of head-to-head comparisons of spironolactone with a thiazide diuretic, spironolactone proved to be at least as effective as the thiazides for correcting hypertension 2 ; and second, spironolactone treatment proved to be considerably more potent than thiazides and/or furosemide for full diuresis of patients with CHF or cirrhosis with ascites, often working after a failed thiazide/Lasix trial. Its power in these latter 2 situations was therefore amazing. Furthermore, these latter results correctly implied a large role for aldosterone excess in the pathogenesis of these conditions.
In addition to cost, however, there are 2 problems with spironolactone that have stalled its acceptance: First is its very gradual action, which made it appear to be less effective and therefore less attractive to anxious physicians and patients. It takes 3 to 5 weeks of daily therapy to express its full effect. This is because spironolactone blocks only that 2% of the daily renal sodium resorption that is governed by aldosterone. At this rate, however, cumulative sodium loss becomes large, so that after 4 weeks or so, it may easily exceed what could be achieved over the same time with a loop diuretic. This scenario is similar to what happens after total adrenalectomy in animals. These animals die of salt loss and/or hyperkalemia (the model counterpart of an Addisonian crisis), but this takes 6 weeks to develop, and the process can of course be delayed or avoided by feeding NaCl. The second problem with spironolactone was that it caused unpleasant dose-related antiandrogenic side effects, especially in the dose of 50 to 100 mg/d used at first. These are gynecomastia in men and menstrual disturbances in women. But as time went on, we learned that this could be largely avoided by giving only 12.5 to 25 mg/d.
With this latter information in hand, one of us (J.H.L.) over the years achieved success after success as a consultant for treating desperate cardiac patients, already receiving full doses of Lasix and an ACE inhibitor, by adding a small daily dose of spironolactone and then observing, time and time again, dramatic natriuresis and diuresis without urinary K ϩ loss but with clearing of all edema fluid plus an obvious improvement in total cardiovascular performance that sometimes added years to the lives of these patients.
The RALES Heart Failure Trial
We shared these experiences and views about spironolactone with Dr John Alexander, with whom we had worked on captopril when he was at Squibb. He had moved to Searle, where he set out to revive interest in their spironolactone product (Aldactone). He planned a clinical trial in CHF. In a test run, they confirmed our experiences that 12.5 to 25 mg/d would be enough to do the job, and with Bert Pitt's leadership, they designed and performed the now famous RALES Trial reported late in 1999. 3 This trial of 1665 patients with severe CHF was planned for 3 years but had to be discontinued after 24 months because the death rate from cardiac causes was already reduced by an amazing 30% in the group that received spironolactone therapy superimposed on their full drug regimen. All of these benefits occurred with only a small (0.3 mm/L) but highly significant increase in plasma K ϩ levels in the treated group.
Muscle K ؉ Depletion: A Common Pathogenic Factor in Thiazide-Treated CHF and Hypertensive Patients
The spectacular results of the RALES trial in CHF patients teach us that sulfonamide-diuretic-induced K ϩ and Mg 2ϩ deficiencies may not be benign. This per se could create serious dysfunction in cardiac and skeletal muscle performances, which, in CHF, might hasten progression of heart failure. This possibility is strongly supported by the large measured deficiencies in muscle K ϩ and Mg 2ϩ with increased muscle Na ϩ content in muscle biopsies of either diuretictreated CHF or diuretic-treated hypertensive patients in studies reported by Dyckner et al 4 -6 (Table 1) . They also demonstrated impressive corrections of those muscle disturbances by superimposed spironolactone therapy, which blocks the kaliuretic and magnesiuretic actions of endogenous aldosterone. These results teach us anew that the K ϩ (and Mg 2ϩ ) loss in these patients is caused or amplified by the diuretic-induced high plasma renin and angiotensin, and thence plasma aldosterone, levels occurring in CHF, which are also induced in hypertensive patients by their similar renin-aldosterone system response to the thiazide-induced sodium-volume loss. [7] [8] [9] Accordingly, this kidney renin secretory response in either CHF or hypertension can be turned off by restoring NaCl to improve volume and flow, after which renin and aldosterone fall dramatically, but this treatment may restore hypertension, and it is not safe to apply in most CHF patients. 7 Thus, in CHF, heart failure begins in the heart with its failure as a pump, 10 leading to poor renal perfusion that causes the kidneys to release renin, causing plasma renin-angiotensin to rise, which in turn stimulates aldosterone release, which causes Na ϩ retention (and edema), but if aldosterone is high and if distal tubular sodium supply is also too high, as occurs with diuretic therapy, 11 kaliuresis will be sustained. Thus, in this setting of chronic diuretic therapy, the volume depletion of thiazide or loop diuretics causes renin and especially, thence, aldosterone 11, 12 to increase, causing aldosterone to maintain chronic kaliuresis. All of this is correctable by spironolactone blockade of the aldosterone receptor. Long ago, Davis 10 demonstrated the crucial role of aldosterone in dog heart failure. This heart failure was dramatically corrected by total adrenalectomy, and then it could be restored by aldosterone replacement. 10 Spironolactone does the same job in patients, albeit much less dramatically or completely than would a surgical adrenalectomy.
Pathogenic Role of Thiazide-Induced K

؉
Depletion in Hypertensive Patients
Great clinical discoveries, like this one from the RALES Trial, 3 revealing a discrete pathogenic role for thiazideinduced increased distal tubular sodium supply enabling the endogenous aldosterone excess to sustain kaliuresis 11 and thereby facilitating the progression of CHF via depletion of myocardial and vascular K ϩ , are often first made in the most egregious forms of a disease. Accordingly, by extrapolating from these findings in CHF, one can recognize the very same long-term thiazide-induced biochemical pathophysiology (ie, high aldosterone and low K ϩ levels) as it occurs, not only in milder forms of heart failure but also in that vast population of diuretic-treated hypertensive patients who are available. Thus, practically all thiazide-treated hypertensive patients do exhibit lower plasma K ϩ levels than before their thiazide therapy.
Hypokalemia With Diuretic Use in the SHEPS Trial
The recent subgroup analysis of the Systolic Hypertension in the Elderly (SHEPS) trial 13 is directly relevant to the latter issue. A subgroup of this study, which used low-dose chlorthalidone, revealed that 7.2% of the treated hypertensive patients exhibited plasma K ϩ values Ͻ3.5.
3 Surprisingly, in these diuretic-treated hypokalemic patients, all of the potential protection from morbid cardiovascular sequelae was lost. 13 This loss of cardioprotection occurred even though (Table 1) . These findings resemble earlier findings in the MRFIT trial of a 2.4-fold greater risk of sudden death associated with higher-dose diuretic therapy. 14, 15 Moreover, these relationships are entirely in keeping with earlier studies by Cannon and colleagues 8, 9 that showed that urinary K ϩ loss in diuretic-treated patients, who have either hypertension or heart failure, is consistently closely related to the height of endogenous aldosterone secretion rates (Figure 1 ). They also showed that the kaliuresis of diuretic therapy does not occur in adrenalectomized patients, thereby proving that it is the aldosterone response to diuretic-induced sodium-volume depletion, not the diuretic itself, that causes the kaliuresis. 9 Moreover, we have learned that higher renin and aldosterone levels in response to diuretic treatment can also reverse its antihypertensive effect. 12 
K ؉ Depletion Impairs Cardiac Performance
We know that body K ϩ depletion can occur without subnormally reduced plasma K ϩ levels, so that what we are seeing in hypokalemic patients could be a tip of the iceberg situation. In this regard, thiazide diuretic treatment of hypertensives is associated with more ventricular arrhythmias 16, 17 and higher sudden death rates, 18 and these events are avoided by spironolactone treatment. 18 In this context, too, it should be related that most diuretic-based long-term trials of hypertensive patients have failed to show significant protection from myocardial infarction. This is in accord with the fact that cardiovascular protection disappeared in the hypokalemic subgroup of the SHEPS trial, even though their blood pressures were reduced even more than in the controls (Table  2) . 3 Thus, Ն6% of diuretic-treated patients are suffering from a second, thiazide-induced, iatrogenic disorder (ie, K ϩ depletion) that more than cancels out the primary purpose of this treatment, to protect from later cardiac morbidity. It follows that if 50 million hypertensive patients took thiazides regularly, this iatrogenic potassium deficiency disorder might afflict Ͼ3 million ambulatory hypertensives.
Two studies by Young and associates illustrate how mild potassium depletion produces impressive impairment of cardiac function in normal dogs and healthy human volunteers. In the dog study, 19 mild K ϩ depletion reduced the maximal rate of filling in response to volume expansion by 51%, and in the human study, a mean K ϩ value of 3.5 reduced peak flow velocity measured by echocardiography by 14%. 20 
K
؉ Depletion Is a Sine Qua Non for Full Expression of Experimental Hypertensive Vascular Damage to Heart, Brain, and Kidney
Vessels in Various Hypertensive Models
In rat genetic hypertension (SHRsp rats), diuretic or dietary K ϩ depletion appears to be a prerequisite for the occurrence of subsequent heart, brain, and kidney vessel cardiac injury, all of which are accordingly corrected or arrested by increasing the dietary K ϩ intake or, even better, by treatment with spironolactone. 21, 22 The converse of these relationships is also true. In a human trial 23 and in our study of stroke-prone hypertensive animals, 24 high K ϩ diets were associated with stroke protection in humans. In the SHRsp rats, K ϩ repletion was associated with impressive reductions in their renin levels and with arrest of vascular pathology in the heart, brain, and kidneys, along with the stroke protection (see Figures 2 and 3) . Several biochemical or cellular mechanisms have been implicated to explain how K ϩ depletion promotes cardiac and vascular injury, which is correctable by K ϩ repletion. Thus, increases in extracellular K ϩ levels within the physiological range in 1-mmol/L increments from 3 to 7 mmol/L causes significant decreases in free radical formation from vascular endothelial cells, smooth muscle proliferation, and induced thrombus formation. 24 With verification, these pathways could prove to be relevant clinical targets for pharmacological control.
In summary, thiazide-induced K ϩ and/or Mg 2ϩ depletion in hypertension and in CHF is probably not benign. It impairs cardiac function, and it creates or enhances the risk of morbid cardiac and vascular events. In hypertensive patients, these effects of K ϩ depletion more than cancel the cardiovascular protective value afforded by the concurrent sizable thiazideinduced reductions in blood pressure. Moreover, increasing dietary K ϩ without also blocking endogenously high aldosterone levels probably has little corrective value in diuretictreated patients, 25 because unless aldosterone is also blocked, the fed K ϩ is directed into the urine by the endogenous aldosterone excess 8, 9 induced in both CHF and hypertensive patients by thiazide diuretic activation of the renin system 8, 9 and by the thiazide action to divert more sodium to the distal nephron. Accordingly, short of stopping the thiazide therapy, the value of specific aldosterone receptor antagonists, such as spironolactone, for treating such patients with hypertension or heart failure appears to be unique for dealing with this iatrogenic predicament. Spironolactone treatment per se, that is, as a replacement for thiazide therapy, could well prove to be an even simpler solution. Newer analogues with possibly even fewer endocrine side effects will be welcome. 
